Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 9, 2011

View Archived Issues

Safety data presented from clinical evaluation of BIBF-1120 in hepatocellular carcinoma

New qRT-PCR-based microRNA profiling technique serves as diagnostic tool in CTCL

Ardea Biosciences provides update on lesinurad development

Results presented from several clinical studies assessing zonisamide in partial epilepsy

Bristol-Myers Squibb describes new chemokine CCR2 receptor antagonists

Boehringer Ingelheim Pharma patents novel therapies for HIV

New nitric oxide donors claimed for diabetes-associated neuropathic pain

Phase I/II data presented on DAC-060 in nonmelanoma skin cancer

Novartis develops novel cyclin-dependent kinase inhibitors

New glycoprotein-Ig fusion proteins generated to elicit immunity against HCV

BioLineRx signs agreement with Tel Aviv University for BL-7050

Pharnext gathers funds for further development of Pleodrug for Charcot-Marie-Tooth disease

Novel recombinant proteins catalyze tRNA aminoacylation

Trophos completes enrollment in pivotal study of olesoxime

Pluristem's PLX cells show promise in preclinical studies

Repros Therapeutics presents phase II data on low-dose Proellex

FDA clears DelMar Pharmaceuticals' IND for phase I/II VAL-083 trial

Bristol-Myers Squibb acquires Amira Pharmaceuticals

FDA committee issues recommendation on rivaroxaban to prevent stroke and systemic embolism in AF

NeurogesX submits sNDA for Qutenza to FDA

Alchemia opens recruitment in phase II HA-irinotecan trial

Spherix combination treatment reduces VLDL and LDL in preclinical study

ME-143 enters clinical development

HUYA Bioscience partners with Chinese university

Enterologics completes acquisition of BioBalance

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...